Shaji Kumar, MD, on Stem Cell Transplantation for Patients with Myeloma

Article

The Mayo Clinic expert spoke about stem cell transplantation for patients with myeloma and the factors that affect the ability to collect stem cells.

Shaji Kumar, MD, from the Mayo Clinic in Rochester, Minnesota, discussed the importance of stem cell transplantation for patients with myeloma and the steps necessary to perform the procedure at the 2020 Transplantation & Cellular Therapy Meetings, held February 19-23, 2020 in Orlando, Florida.

Transcription:

Stem cell transplantation remains an important part of myeloma therapy in patients who are eligible to go through a stem cell transplant and this often includes patients all the way up to 75 years in age, as long as they have good performance jettison, good organ function. So, the ability to collect stem cells for autologous stem cell transplantation is important in myeloma. There are a variety of different factors that affect the ability to collect stem cells and these include the type and the duration of therapy they receive before they go to a stem cell transplant, and as well as the degree of disease control. In the younger patients, we often try to collect adequate numbers of cells for 2 to 3 stem cell transplantation, which can then be used either as tandem order transplants or salvage order transplant at the time of relapse. So, it’s important we are able to collect adequate numbers and a variety of different approaches have been tried…all of which depends on the particular clinical context.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
Related Content